PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

NCT ID: NCT00472043

Last Updated: 2024-08-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 66 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2000-10-01
• Study Completion Date: 2002-09-30

Brief Summary

Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells. The photosensitiser generated reactive oxygen species upon illumination.

For skin diseases, there had been an increasing interest in using precursors of the endogenous photosensitiser protoporphyrin IX (PpIX). The most commonly used precursors had been 5-aminolevulinic acid (ALA) and its derivatives. The present test drug, Metvix®, contained the methyl ester of ALA, which penetrated the lesions well and shows high lesion selectivity .

In vitro studies of animal and human tissues had shown significant intracellular formation of photoactive porphyrins after addition of Metvix®. The increased levels of photoactive porphyrins induced cytotoxic effects in tumour cells after photoactivation.

The primary objective was to compare PDT with Metvix® cream to PDT with placebo cream in terms of participant complete response rates based on histologically verified disappearance of the lesions at 6 months after last treatment cycle.

Secondary objectives were to compare the two treatments in terms of histological and clinical mean participant response weighted by the number of lesions within a participant, lesion response rates across participants, clinical complete participant response, cosmetic outcome and adverse events.

Detailed Description

A participant was randomised to PDT with Metvix® cream or PDT with placebo cream. All eligible Basal cell carcinoma (BCC) lesions within a participant had got the same treatment. All participants got two consecutive treatments one week apart. At the 3-months follow-up visit, lesions with no clinical response or progression had been surgically excised. Lesions with partial response (50% or greater reduction on lesion area) had been re-treated, if they do not show complete response three months later they would have been be surgically excised. Lesions with complete response had been surgically excised 6 months after the first or second PDT cycle. All excised tissue specimens had been histologically examined.

Conditions

Basal Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Metvix® cream 160 milligram per gram

Methyl aminolevulinate hydrochloride 160 milligram (mg)/gram (g) cream were received by participants with primary nodular basal cell carcinoma. A thick layer of study cream was applied directly on the lesion and on 5 mm of the surrounding tissue. An approximately 1 mm thick layer of cream was applied to cover the lesion completely. The study cream was applied for at least 3 hours followed by illumination using non-coherent red (570-670 nm) light at a fluence of 50- 75 J/cm\^2.

Group Type: EXPERIMENTAL

PDT with Metvix 160 mg/g cream

Intervention Type: DRUG

Placebo

Participants with primary nodular basal cell carcinoma received Metvix® matching placebo cream. A thick layer of study cream was applied directly on the lesion and on 5 mm of the surrounding tissue. An approximately 1 mm thick layer of cream was applied to cover the lesion completely. The study cream was applied for at least 3 hours followed by illumination using non-coherent red (570-670 nm) light at a fluence of 50- 75 J/cm\^2.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

PDT with Metvix 160 mg/g cream

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

A participant with primary, nodular BCC lesion(s) suitable for entry is defined as a participant with

• Clinically diagnosed primary nodular BCC lesion(s).
• Histologically confirmed diagnosis of BCC.
• BCC lesions suitable for simple excision surgery.
• Males or females above 18 years of age.
• Written informed consent.

Exclusion Criteria

A participant that is ineligible for inclusion is a participant fulfilling any of the following criteria:

• Participants with porphyria.
• Participant with Gorlin's syndrome.
• Participant with Xeroderma pigmentosum.
• Participants concurrently receiving immunosuppressive medication.
• Participants with a history of arsenic exposure.
• Known allergy to Metvix®, a similar PDT compound or excipients of the cream.
• Participation in other clinical studies either concurrently or within the last 30 days.
• Pregnant or breast-feeding: All women of child-bearing potential must use adequate contraception (e.g. barrier methods, oral contraceptives or intrauterine device) during the treatment period and one month thereafter. In addition, they must have a negative pregnancy test prior to treatment.
• Conditions associated with a risk of poor protocol compliance.

• A nodular BCC lesion in periorbital area, ears and nasolabial fold.
• A nodular BCC lesion with the longest diameter less than 6 mm or larger than 15 mm in face/scalp, larger than 20 mm on extremities and neck and larger than 30 mm on truncus.
• Pigmented nodular BCC lesion(s).
• Morpheaform nodular BCC lesion(s).
• Infiltrating nodular BCC lesion(s).
• Prior treatment of the BCC lesion(s).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Galderma R&D

INDUSTRY

Sponsor Role: lead

Principal Investigators

Peter Foley, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Dermatology, St. Vincent's Hospital Melbourne

Locations

Dept. of Dermatology, Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Dermatology Dept., St. George Hospital

Kogarah, New South Wales, Australia

Dermatology Centre

Liverpool, New South Wales, Australia

Dr. Michael Freeman

Benowa, Queensland, Australia

Dermatology Dept., Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Department of Dermatology, St. Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia

Fremantle Dermatology

Fremantle, Western Australia, Australia

Countries

Australia

Other Identifiers

PC T308/00

Identifier Type: -

Identifier Source: org_study_id